XML 18 R7.htm IDEA: XBRL DOCUMENT
v3.26.1

Description of Business | 6 Months Ended
--- | ---
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Description of Business | Description of Business Description of Business Evolus, Inc., (“Evolus” or the “Company”) is a global performance beauty company focused on delivering products in the cash-pay aesthetic market. The Company’s portfolio includes Jeuveau® (prabotulinumtoxinA-xvfs), a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as “frown lines,” in adults and Evolysse®, a collection of injectable hyaluronic acid (“HA”) gels. Evolysse® Form and Evolysse® Smooth were launched in the United States in April 2025 and are indicated for wrinkles and folds, such as nasolabial folds, in adults. The Company anticipates two additional Evolysse® products, Evolysse® Sculpt and Evolysse® Lips, to be approved in the United States in the fourth quarter of 2026 and 2027, respectively. In May 2026, the Company launched four Evolysse® products in Europe. The Company is headquartered in Newport Beach, California. Liquidity and Financial Condition The accompanying unaudited condensed consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of the Company’s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Since inception, the Company has incurred recurring net operating losses and negative cash flows from operating activities. In the three and six months ended June 30, 2026, the Company recorded a loss from operations of $4,543 and $11,391, respectively, and a net loss of $8,052 and $18,726, respectively. The Company used $13,539 of cash from operations during the six months ended June 30, 2026. As of June 30, 2026, the Company had $45,170 in cash and cash equivalents and an accumulated deficit of $679,766. The Company believes that its current capital resources, which consist of cash and cash equivalents, future cash generated from operations, availability of liquidity under both the New Pharmakon Term Loans and the Revolving Credit Facility (as defined in Note 7. Long-Term Debt and below, respectively) and other existing liquidity, will be sufficient to fund its operations through at least the next twelve months from the date the accompanying condensed consolidated financial statements are issued based on its expected cash needs. On March 3, 2026, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with the Company, as borrower, and Eclipse Business Capital LLC as administrative agent and the lenders party thereto. Pursuant to the Loan Agreement, the lenders party provided a senior secured asset-based revolving credit facility (the “Revolving Credit Facility”) with a $30,000 commitment and an uncommitted accordion feature of up to $10,000, which is exercisable, subject to lenders party consent and other conditions, in $5,000 increments or in its entirety. The Revolving Credit Facility has a minimum utilization requirement of $10,000 and matures on March 3, 2029 with outstanding principal and interest fully due and payable at such time. See Note 7. Long-Term Debt for additional information. On May 5, 2025, the Company entered into an Amended and Restated Loan Agreement (the “A&R Loan Agreement”) with Pharmakon (as defined in Note 7. Long-Term Debt), pursuant to which Pharmakon agreed to provide the Company with a senior secured term loan of up to $250,000 in aggregate principal. The term loan is to be funded in three tranches comprised of an initial $150,000 tranche funded upon the execution of the A&R Loan Agreement and two additional tranches of up to $50,000 each, available at the Company’s election no later than December 31, 2026. In addition, under the terms of the A&R Loan Agreement, the Company is permitted to incur additional indebtedness in the form of a working capital or revolving loan facility with a maximum credit line of no more than $40,000 at any time, subject to Pharmakon’s consent and certain terms and conditions customary for credit facilities of similar size and type. On May 1, 2026, the Company terminated the At-the-Market Sales Agreement (the “ATM Sales Agreement”) with Leerink Partners LLC, which the Company had entered into in March 2023. The ATM Sales Agreement provided for the offer and sale, from time to time, of shares of the Company’s common stock for an aggregate gross proceeds of up to $50,000. The Company had not sold any shares under the ATM Sales Agreement prior to its termination. See Note 10. Stock-Based Compensation and Stockholders’ Equity for additional information.

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.4-03(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContent Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration